On October 3, 2022 Median Technologies (Paris:ALMDT) reported the formation of their Clinical Advisory Board (CAB) for iBiopsy Lung Cancer Screening (Press release, MEDIAN Technologies, OCT 3, 2022, View Source [SID1234621645]). This group of world class physicians brings comprehensive expertise in the space of Lung Cancer Screening to guide Median in the development of iBiopsy LCS AI/ML tech-based CADe/CADx SaMD (software as medical device), which detects and characterizes lung cancer nodules in high risk populations, ultimately aimed at improving patient outcomes as well as clinical workflows.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are privileged to have the opportunity to bring together this group of truly world-class physicians and academic leaders, who’s expertise and invaluable insights will help guide our late stage development as we approach pivotal clinical studies towards regulatory approval, and beyond" said Thomas Bonnefont, iBiopsy COO and CCO at Median.
"I am pleased and honored to be working with this team of distinguished and highly accomplished clinicians, who’s wealth of knowledge and experience will help Median deliver on optimizing the Lung Cancer Screening routine and saving patient lives." said Yan Liu M.D., Chief Medical Officer of Median
Introducing the members of Clinical Advisory Board for Lung Cancer Screening (in alphabetical order):
Philippe Grenier
Professor, Thoracic Radiologist and Head of the Artificial Intelligence project, Hopital Foch, Suresnes (France)
Francesco Grossi
Director of the Division of Medical Oncology and Associate Professor at the University of Insubria, Varese (Italy)
Luis Seijo Maceiras
Director of Pneumology Department – Clinica Universidad de Navarra, Madrid (Spain)
Carey Thomso
Chair, Department of Medicine and Director, Multidisciplinary Thoracic Oncology and Lung Cancer Screening Program, Mount Auburn Hospital/Beth Israel Lahey Health, Cambridge, Massachusetts (United States) – Associate Professor of Medicine at Harvard Medical School, Boston, Massachussets (United States)
Anil Vachani
Director of Clinical Research, Section of Interventional Pulmonary and Thoracic Oncology, Penn Medicine, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia (United States)
David Yankelevitz
Professor of Radiology and Director of the Lung Biopsy Service at the Icahn School of Medicine, Mount Sinai, New York City (USA)
Javier Zulueta
Senior Faculty and Chief of the Division of Medicine (Pulmonary, Critical Care and Sleep Medicine) at Mount Sinai Morningside, Professor of Medicine, Icahn School of Medicine, Mount Sinai, New York City (USA)
About iBiopsy: iBiopsy is based on the most advanced technologies in Artificial Intelligence (AI) and Data Science (DS), benefiting from Median’s expertise in medical image processing. iBiopsy targets the development of innovative AI/ML-based Software as Medical Device, to be used in several indications for which there are unmet needs regarding early diagnosis, prognosis and treatment selection in the context of precision medicine. iBiopsy currently focuses on lung cancer, liver cancer (HCC) and liver fibrosis (NASH).